Ivonescimab Combined With Chemotherapy for EGFR Mutant NSCLC With Leptomeningeal Metastasis After EGFR TKIs Resistance: A Multicenter Observational Study.
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Ivonescimab (Primary)
- Indications Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Jan 2025 New trial record